On 15 April, a regular meeting of the RSPP Coronavirus Response Coordination Council was held via video conference. The meeting was chaired by Viktor Cherepov, Deputy Chairman of the Council, and Vice-President of the RSPP for Social Policy and Labour Relations.
According to a representative of Rospotrebnadzor [The Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing], on 5 April the first large batch of the EpiVacCorona vaccine, consisting of more than 230 thousand kits, was sent to more than 40 constituent entities of the Russian Federation. Rospotrebnadzor estimates that by the end of month, the number of doses produced will reach 1.5 million. It is planned to achieve herd immunity by vaccinating 60% of the population.
The EpiVacCorona vaccine consists of three synthetic fragments of spike, attached to a carrier protein, which induce an immune response in humans. The vaccine does not cause allergic reactions.
The A.A. Smorodintsev Influenza Research Institute spoke about its own COVID-19 vaccine.
The intranasal vaccine is based on an attenuated influenza virus and uses technology similar to Sputnik V, where an adenovirus is used as a “container” to deliver the coronavirus gene
Vaccine trials will begin in the autumn. Its main advantages are: no risks of potentiating infection, low cost and possibility of large-scale production in a short time, export potential when using GMP-standards for vaccine production, as well as the added benefit of protecting against seasonal influenza A.
Mikhail Tsyferov, President of NPO Petrovax Pharm, spoke about the development and production of the company’s Convidecia vaccine.
Together with Chinese partner CanSino, in 2020-2021 a new Covid-19 vaccine, Convidetsia, was developed, and this year it was produced at the Petrovax pharmaceutical complex in Moscow oblast.
The vaccine trial involved 44,000 volunteers around the world. The vaccine has been approved in China, Mexico, Pakistan and Hungary.
Laboratory studies have shown that the vaccine is effective against ten strains of SARS-CoV-2, including the British and South African strains.